Initial Two Doses of COVID-19 Vaccine mRNA-1273 for an Individual Previously Vaccinated with Two Doses of an Inactivated Vaccine CoronaVac That Has Not Been Approved in Japan

Yoshiaki Iwasaki; Chigusa Higuchi

doi:10.18926/AMO/64370

Initial Two Doses of COVID-19 Vaccine mRNA-1273 for an Individual Previously Vaccinated with Two Doses of an Inactivated Vaccine CoronaVac That Has Not Been Approved in Japan

Yoshiaki Iwasaki, Chigusa Higuchi

Health Service Center

Research output: Contribution to journal › Article › peer-review

Abstract

The inactivated coronavirus disease 2019 vaccine CoronaVac has not been approved in Japan. Little information is available on cases in Japan in which an approved mRNA vaccine was administered as the initial (first or second) dose after two doses of CoronaVac. Furthermore, the safety and efficacy of this combination are not established. We here evaluated the safety and efficacy in a patient who showed an antibody response to an approved vaccine, mRNA-1273, after a previous vaccination with CoronaVac. The adverse events consisted of only mild local and systemic common reactions and were transient. In addition, a strong and persistent antibody response was observed.

Original language	English
Pages (from-to)	105-109
Number of pages	5
Journal	Acta medica Okayama
Volume	77
Issue number	1
DOIs	https://doi.org/10.18926/AMO/64370
Publication status	Published - Feb 1 2023

Keywords

adverse events
antibody response
coronavirus disease 2019
severe acute respiratory syndrome coronavirus 2
vaccine

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.18926/AMO/64370

Cite this

@article{ba029a04b51f42b59a669b2d46c4fc74,

title = "Initial Two Doses of COVID-19 Vaccine mRNA-1273 for an Individual Previously Vaccinated with Two Doses of an Inactivated Vaccine CoronaVac That Has Not Been Approved in Japan",

abstract = "The inactivated coronavirus disease 2019 vaccine CoronaVac has not been approved in Japan. Little information is available on cases in Japan in which an approved mRNA vaccine was administered as the initial (first or second) dose after two doses of CoronaVac. Furthermore, the safety and efficacy of this combination are not established. We here evaluated the safety and efficacy in a patient who showed an antibody response to an approved vaccine, mRNA-1273, after a previous vaccination with CoronaVac. The adverse events consisted of only mild local and systemic common reactions and were transient. In addition, a strong and persistent antibody response was observed.",

keywords = "adverse events, antibody response, coronavirus disease 2019, severe acute respiratory syndrome coronavirus 2, vaccine",

author = "Yoshiaki Iwasaki and Chigusa Higuchi",

year = "2023",

month = feb,

day = "1",

doi = "10.18926/AMO/64370",

language = "English",

volume = "77",

pages = "105--109",

journal = "Acta medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "1",

}

TY - JOUR

T1 - Initial Two Doses of COVID-19 Vaccine mRNA-1273 for an Individual Previously Vaccinated with Two Doses of an Inactivated Vaccine CoronaVac That Has Not Been Approved in Japan

AU - Iwasaki, Yoshiaki

AU - Higuchi, Chigusa

PY - 2023/2/1

Y1 - 2023/2/1

N2 - The inactivated coronavirus disease 2019 vaccine CoronaVac has not been approved in Japan. Little information is available on cases in Japan in which an approved mRNA vaccine was administered as the initial (first or second) dose after two doses of CoronaVac. Furthermore, the safety and efficacy of this combination are not established. We here evaluated the safety and efficacy in a patient who showed an antibody response to an approved vaccine, mRNA-1273, after a previous vaccination with CoronaVac. The adverse events consisted of only mild local and systemic common reactions and were transient. In addition, a strong and persistent antibody response was observed.

AB - The inactivated coronavirus disease 2019 vaccine CoronaVac has not been approved in Japan. Little information is available on cases in Japan in which an approved mRNA vaccine was administered as the initial (first or second) dose after two doses of CoronaVac. Furthermore, the safety and efficacy of this combination are not established. We here evaluated the safety and efficacy in a patient who showed an antibody response to an approved vaccine, mRNA-1273, after a previous vaccination with CoronaVac. The adverse events consisted of only mild local and systemic common reactions and were transient. In addition, a strong and persistent antibody response was observed.

KW - adverse events

KW - antibody response

KW - coronavirus disease 2019

KW - severe acute respiratory syndrome coronavirus 2

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85148971319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85148971319&partnerID=8YFLogxK

U2 - 10.18926/AMO/64370

DO - 10.18926/AMO/64370

M3 - Article

C2 - 36849154

AN - SCOPUS:85148971319

SN - 0386-300X

VL - 77

SP - 105

EP - 109

JO - Acta medica Okayama

JF - Acta medica Okayama

IS - 1

ER -

Initial Two Doses of COVID-19 Vaccine mRNA-1273 for an Individual Previously Vaccinated with Two Doses of an Inactivated Vaccine CoronaVac That Has Not Been Approved in Japan

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this